Literature DB >> 18175324

Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.

Maturos Malaisree1, Thanyada Rungrotmongkol, Panita Decha, Pathumwadee Intharathep, Ornjira Aruksakunwong, Supot Hannongbua.   

Abstract

To provide detailed information and insight into the drug-target interaction, structure, solvation, and dynamic and thermodynamic properties, the three known-neuraminidase inhibitors-oseltamivir (OTV), zanamivir (ZNV), and peramivir (PRV)-embedded in the catalytic site of neuraminidase (NA) subtype N1 were studied using molecular dynamics simulations. In terms of ligand conformation, there were major differences in the structures of the guanidinium and the bulky groups. The atoms of the guanidinium group of PRV were observed to form many more hydrogen bonds with the surrounded residues and were much less solvated by water molecules, in comparison with the other two inhibitors. Consequently, D151 lying on the 150-loop (residues 147-152) of group-1 neuraminidase (N1, N4, N5, and N8) was considerably shifted to form direct hydrogen bonds with the --OH group of the PRV, which was located rather far from the 150-loop. For the bulky group, direct hydrogen bonds were detected only between the hydrophilic side chain of ZNV and residues R224, E276, and E277 of N1 with rather weak binding, 20-70% occupation. This is not the case for OTV and PRV, in which flexibility and steric effects due to the hydrophobic side chain lead to the rearrangement of the surrounded residues, that is, the negatively charged side chain of E276 was shifted and rotated to form hydrogen bonds with the positively charged moiety of R224. Taking into account all the ligand-enzyme interaction data, the gas phase MM interaction energy of -282.2 kcal/mol as well as the binding free energy (DeltaG(binding)) of -227.4 kcal/mol for the PRV-N1 are significantly lower than those of the other inhibitors. The ordering of DeltaG(binding) of PRV < ZNV < OTV agrees well with the ordering of experimental IC(50) value. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175324     DOI: 10.1002/prot.21897

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  12 in total

1.  Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Authors:  Mélanie Samson; Yacine Abed; François-Marc Desrochers; Stephanie Hamilton; Angela Luttick; Simon P Tucker; Melinda J Pryor; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase.

Authors:  Jiraphorn Phanich; Thanyada Rungrotmongkol; Daniel Sindhikara; Saree Phongphanphanee; Norio Yoshida; Fumio Hirata; Nawee Kungwan; Supot Hannongbua
Journal:  Protein Sci       Date:  2015-06-22       Impact factor: 6.725

3.  The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.

Authors:  Nalini Schaduangrat; Jiraphorn Phanich; Thanyada Rungrotmongkol; Hatairat Lerdsamran; Pilaipan Puthavathana; Sukathida Ubol
Journal:  J Gen Virol       Date:  2016-03-02       Impact factor: 3.891

4.  Molecular-level simulation of pandemic influenza glycoproteins.

Authors:  Rommie E Amaro; Wilfred W Li
Journal:  Methods Mol Biol       Date:  2012

5.  Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus.

Authors:  Mao Shu; Zhihua Lin; Yunru Zhang; Yuqian Wu; Hu Mei; Yongjun Jiang
Journal:  J Mol Model       Date:  2010-06-03       Impact factor: 1.810

6.  Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.

Authors:  Jiraphorn Phanich; Thanyada Rungrotmongkol; Nawee Kungwan; Supot Hannongbua
Journal:  J Comput Aided Mol Des       Date:  2016-10-06       Impact factor: 3.686

7.  Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design.

Authors:  Jacob D Durrant; J Andrew McCammon
Journal:  Comput Biol Chem       Date:  2010-04-03       Impact factor: 2.877

8.  Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza.

Authors:  Ly Le; Eric Lee; Klaus Schulten; Thanh N Truong
Journal:  PLoS Curr       Date:  2009-08-27

9.  Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.

Authors:  Morgan Lawrenz; Jeff Wereszczynski; Rommie Amaro; Ross Walker; Adrian Roitberg; J Andrew McCammon
Journal:  Proteins       Date:  2010-08-15

10.  Independent-Trajectories Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by Peramivir.

Authors:  Morgan Lawrenz; Riccardo Baron; J Andrew McCammon
Journal:  J Chem Theory Comput       Date:  2009-03-25       Impact factor: 6.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.